|
**Overview**: Oral Glucose Tolerance Test Panel**Introduction**: The Oral Glucose Tolerance Test Panel is a diagnostic tool designed to assess glucose tolerance using plasma samples. In India, OGTT (75g, 2-hour) is gold standard for diagnosing diabetes/impaired tolerance (~11 percent diabetes prevalence), especially in prediabetes screening. High morbidity from under-testing in rural/low-SES adults with risk factors, limited labs, delayed lifestyle/metformin leading to progression to diabetes. Per endocrinology practices aligned with ICMR and RSSDI guidelines, the test employs spectrophotometry for fasting/2-hour glucose over 1-2 days with high accuracy, valuable for definitive diagnosis. This diagnostic falls under glucose tolerance screening and targets patients with prediabetes risk or symptoms, addressing accurate detection to guide intervention. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise glucose assessment and reducing diabetes burden. Its plasma-based approach ensures reliable measurement.**Other Names**: OGTT Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: OGTT standard; in India, used in diabetes programs.**Purpose**: The test assesses 2 parameters including fasting glucose to guide glucose tolerance evaluation, detect diabetes/prediabetes, inform therapy.**Test Parameters**: 1. Fasting Glucose, 2. 2-Hour Glucose.**Pretest Condition**: Fasting 10-12 hours required; patients should report risk factors or symptoms.**Specimen**: 3 mL plasma in NaF tube (multiple draws), transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on family diabetes, obesity, symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated dysglycemia including diabetes, benefits of assessment, and minimal discomfort from multiple draws.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or non-compliance with load can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal values diagnose diabetes/prediabetes, necessitating specialist input.**Specialist Consultation**: Diabetologists should be consulted for management.**Additional Supporting Tests**: HbA1c, fasting glucose for confirmation.**Test Limitations**: Time-consuming; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Diabetes Studies India 2023. |
